Atossa Genetics (NASDAQ:ATOS) Announces Quarterly Earnings Results, Misses Expectations By $0.32 EPS

Atossa Genetics (NASDAQ:ATOS) released its quarterly earnings data on Tuesday. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.32), Fidelity Earnings reports.

ATOS opened at $2.46 on Wednesday. The firm’s fifty day simple moving average is $2.20. Atossa Genetics has a 52-week low of $0.80 and a 52-week high of $7.39. The stock has a market cap of $20.71 million, a PE ratio of -0.45 and a beta of 3.33.

Several research analysts have issued reports on the company. Maxim Group cut Atossa Genetics from a “buy” rating to a “hold” rating in a research report on Thursday, June 27th. ValuEngine raised Atossa Genetics from a “hold” rating to a “buy” rating in a research note on Thursday, June 27th.



Atossa Genetics Company Profile

Atossa Genetics Inc a clinical-stage pharmaceutical company, focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the United States. The company is conducting a Phase 2 clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in situ and breast cancer; and a pharmaceutical program under development is Endoxifen, an active metabolite of tamoxifen, as well as treatment for breast density and other breast health conditions.

Read More: Quick Ratio

Earnings History for Atossa Genetics (NASDAQ:ATOS)

Receive News & Ratings for Atossa Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Genetics and related companies with MarketBeat.com's FREE daily email newsletter.